Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
3.840
-0.150 (-3.76%)
At close: Nov 16, 2026, 4:00 PM EST
3.925
+0.085 (2.20%)
After-hours: Nov 16, 2026, 7:59 PM EST
Nuvation Bio Employees
Nuvation Bio had 310 employees as of September 30, 2026. The number of employees increased by 19 or 6.53% compared to the same quarter last year. That makes Nuvation Bio the 23,618th largest employer in the world and 3,034th in the United States.
Employees
310
Change (1Y)
19
Growth (1Y)
6.53%
Revenue / Employee
$650,745
Profits / Employee
-$438,497
Market Cap
1.36B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 310 | 19 | 6.53% |
| Jun 30, 2026 | 305 | 27 | 9.71% |
| Mar 31, 2026 | 307 | 34 | 12.45% |
| Dec 31, 2025 | 298 | 78 | 35.45% |
| Sep 30, 2025 | 291 | 88 | 43.35% |
| Jun 30, 2025 | 278 | 111 | 66.47% |
| Mar 31, 2025 | 273 | 114 | 71.70% |
| Dec 31, 2024 | 220 | 169 | 331.37% |
| Sep 30, 2024 | 203 | 150 | 283.02% |
| Jun 30, 2024 | 167 | 113 | 209.26% |
| Mar 31, 2024 | 159 | 106 | 200.00% |
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Sep 30, 2023 | 53 | -1 | -1.85% |
| Jun 30, 2023 | 54 | -31 | -36.47% |
| Mar 31, 2023 | 53 | -15 | -22.06% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Sep 30, 2022 | 54 | -4 | -6.90% |
| Jun 30, 2022 | 85 | 34 | 66.67% |
| Mar 31, 2022 | 68 | 30 | 78.95% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| Intellia Therapeutics | 377 |
| Ocular Therapeutix | 325 |
| Structure Therapeutics | 281 |
| Innoviva | 159 |
| Absci | 140 |
| AnaptysBio | 104 |
| Tyra Biosciences | 87 |
NUVB News
- 14 hours ago - Nuvation Bio’s safusidenib shows benefits in Phase 2 IDH1-mutant glioma study - TheFly
- 14 hours ago - Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting - PRNewsWire
- 6 days ago - Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London - PRNewsWire
- 7 days ago - Nuvation Bio price target lowered to $11 from $13 at JPMorgan - TheFly
- 11 days ago - Nuvation Bio price target lowered to $13 from $14 at B. Riley - TheFly
- 12 days ago - Nuvation Bio Earnings Call Transcript: Q3 2026 - Transcripts
- 12 days ago - Nuvation Bio Quarterly report: Q3 2026 - Filings
- 12 days ago - Nuvation Bio Earnings release: Q3 2026 - Filings